Synovial sarcoma future or investigational therapies: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
== Future or Investigational Therapies == | == Future or Investigational Therapies == | ||
Further investigation of the molecular mechanisms underlying SYT-SSX function will likely lead to not only a better understanding of this disease but improved diagnostic and treatment tools for this tumor. | Further investigation of the molecular mechanisms underlying SYT-SSX function will likely lead to not only a better understanding of this disease but improved diagnostic and treatment tools for this tumor. Recent laboratory-based studies have identified a number of potential systemic therapies that may prove more effecacious than conventional chemotherapy and improve survival, however the rarity of this tumor makes clinical trial organization difficult and validation of these experimental therapeutics will likely be long in coming. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
Latest revision as of 19:55, 28 August 2015
|
Synovial sarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Synovial sarcoma future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Synovial sarcoma future or investigational therapies |
|
Synovial sarcoma future or investigational therapies in the news |
|
Blogs on Synovial sarcoma future or investigational therapies |
|
Risk calculators and risk factors for Synovial sarcoma future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Further investigation of the molecular mechanisms underlying SYT-SSX function will likely lead to not only a better understanding of this disease but improved diagnostic and treatment tools for this tumor. Recent laboratory-based studies have identified a number of potential systemic therapies that may prove more effecacious than conventional chemotherapy and improve survival, however the rarity of this tumor makes clinical trial organization difficult and validation of these experimental therapeutics will likely be long in coming.